By Liz Kowalczyk
The Boston Globe

Consumer advocates have been pushing for rules that require companies to disclose the full nature of their relationships with physicians, but biotechnology and pharmaceutical companies have been lobbying the Department of Public Health, which wrote the regulations, to exempt the disclosure of payments to doctors for research and research-related activities, arguing that such public scrutiny would scare off companies from funding clinical trials in Massachusetts.

In the proposed regulations, the department states that it sought to limit undue industry influence over physicians' prescribing behavior while not hampering research and requiring disclosure of trade secrets.

To read the complete article click here.